Rx Industry’s Mission Will Change Under Medicare, Scully Declares
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaceutical companies have no idea “how massive the changes that are coming for prescription drugs are,” the former CMS administrator says. The new test for a product’s success will be “what’s Medicare going to pay for it?”
You may also be interested in...
Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
Introduction of certain types of successor drugs as the original product nears patent expiration has "caught the attention" of individuals at FTC, Commissioner Harbour tells BIO annual conference. A company's history and methods of engaging in this practice to blunt generic competition could open it up to agency scrutiny, she says.
Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
Introduction of certain types of successor drugs as the original product nears patent expiration has "caught the attention" of individuals at FTC, Commissioner Harbour tells BIO annual conference. A company's history and methods of engaging in this practice to blunt generic competition could open it up to agency scrutiny, she says.
Pharma Should Share Drug Targets With NIH, Sanofi-Aventis Exec Says
Manufacturers should look for partnerships with the government to improve the level of innovation, Sanofi-Aventis Head of Integrated Markets O’Neil tells The Economist roundtable. Firms should partner with payors early to head off “functional equivalence” decisions.